✦ LIBER ✦

Results From a Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trial Comparing Denosumab with Zoledronic Acid for the Management of Bone Metastases in Patients with Advanced Solid Tumors or Multiple Myeloma

✍ Scribed by Roger von Moos; David Henry; Saroj Vadhan-Raj; Vania Hungria; Andrew Spencer; Vera Hirsh; Jianming Wang; Jun Susie; Yeh Howard; Roger Dansey

Book ID: 116322790
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 58 KB
Volume: 46
Category: Article
ISSN: 8756-3282
DOI: 10.1016/j.bone.2010.01.098

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a prospective, randomized, do

Results of a prospective, randomized, double-blind, double-dummy, Phase 3 study comparing denosumab with zoledronic acid for the treatment of breast cancer patients with bone metastases

✍ Jean-Jacques Body; Alison Stopeck; Yasuhiro Fujiwara; Allan Lipton; Guenther Ste 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Incidence and outcomes of osteonecrosis

Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma

✍ J.E. Brown*; C.H. Barrios; I.J. Diel; T. Facon; K. Fizazi; T. Ibrahim; F. Saad; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Long-term efficacy and safety of zoledro

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma : A randomized, double-blind, multicenter, comparative trial

✍ Lee S. Rosen; David Gordon; Mary Kaminski; Anthony Howell; Andrew Belch; John Ma 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## BACKGROUND The goal of the current study was to compare the long‐term (25‐month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma. ## METHODS Patients (__n__ = 1648) were randomized to